http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Thermal performance investigation of enhanced receiver tube for concentrated solar collector
Mohammed Al-Harrasi,Afzal Husain,M. Zunaid Techno-Press 2022 Advances in energy research Vol.8 No.3
This study presents an experimental investigation of conventional and enhanced receiver tube performance for the application of a concentrated parabolic trough collector (CPC). The CPC system is fabricated and tested for the conventional and enhanced receiver tubes. The experiments were performed on both tubes for the change of flow rates. The temperature rise of the tube surface, as well as working fluid, were monitored for varying flow rates. The results were compared and discussed in view of enhanced CPC system performance. The results exhibited that the temperature rise of the working fluid passing through the tube was more in the case of the enhanced tube compared to the conventional receiver tube under the same flow rates.
Nizwaside: a new anticancer pregnane glycoside from the sap of Desmidorchis flava
Hidayat Hussain,Ahmed Al-Harrasi,Muhammad Adil Raees,Najeeb Ur Rehman,Ahmed Al-Rawahi,Rene´ Csuk,Husain Yar Khan,Ghulam Abbas,Mohammed Abdullah Al-Broumi,Ivan R. Green,Ali Elyassi,Talat Mahmood 대한약학회 2015 Archives of Pharmacal Research Vol.38 No.12
The sap from the succulent Desmidorchis flava (N.E.Br) Meve and Liede yielded a new pregnane glycoside, named nizwaside whose structure was established using 1D and 2D NMR techniques as well as mass spectrometry (ESIMS). Nizwaside was tested for anticancer, DPPH antioxidant, urease enzyme inhibition, a-glucosidase enzyme inhibition and acetylcholinesterase inhibition activities. Interestingly, nizwaside showed significant anti-proliferative effects on MDA MB231 breast cancer cells with an IC50 of 23.5 lg/ml. Moreover, nizwaside was more effective than Doxorubicin, a wellknown clinical anticancer drug, in suppressing MDA MB231 cell proliferation even at concentrations lower than that of Doxorubicin (75 lg/ml nizwaside vs. 100 lg/ml Doxorubicin). On the other hand, nizwaside showed relatively weak antioxidant activity with 15 % inhibition.